On November 11, 2025, in Beijing, Medimscience Biomedical Technology is honored to sign a cooperation intention agreement with Merck's R&D China Innovation Cooperation Center. As one of the world's most important MNCs in the field of medicine and health, Merck has always led the innovation direction in the treatment of major diseases and continues to work hard in promoting breakthrough therapy research and development.
Medimscience Biomedical Technology is deeply involved in the research and development of original innovative drugs targeting macrophages, and has established a rich innovation pipeline matrix in key major disease fields such as autoimmune diseases and tumors. This collaboration between the two parties will further accelerate the development of innovative drugs in the field of refractory diseases, ultimately bringing better treatment options to patients worldwide and jointly contributing to the improvement of human health and well-being.
Link: 首届默沙东研发中国科学日在京成功举办
Souce: 美赛生物 2025-12-09